Medicine composition containing compound 20-(R)-notoginsenoside Ft1 and application of medicine composition in pharmacy
A technology of notoginseng saponins and compounds, applied in the field of medicine, can solve the problems of undiscovered compound application, undiscovered and the like
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0029] Preparation of 20-(R)-notoginsenoside Ft1 (20-(R)-notoginsenoside Ft1):
[0030] The stems and leaves of notoginseng are extracted with 10 times the amount of 1% HCl solution, extracted twice, each time for 2 hours, the filtrates are combined, the pH is adjusted to 7 with 3% NaOH solution, concentrated and dried to obtain a dry paste. Dry paste 100g, mix the sample with silica gel (200-300 mesh) and carry out silica gel column chromatography, use chloroform: methanol: water (8:2:0.2) as eluent, thin layer chromatography checks and merges the same color point Fractions, Fr1-5 fractions were obtained. Fr4 (5g) is carried out repeatedly silica gel column chromatography with chloroform: methanol: water (8:2:0.2) as eluent, and reverse phase silica gel RP-18 column chromatography (methanol: water / 8:2), obtains 20 -(R)-Notoginsenoside Ft1 (0.16 g).
[0031] Structural identification of 20-(R)-notoginsenoside Ft1 (20-(R)-notoginsenoside Ft1):
[0032] Instrument: mass spect...
Embodiment 2
[0039] In vivo anti-tumor activity experiment of 20-(R)-notoginsenoside Ft1 (20-(R)-notoginsenosideFt1):
[0040] 1. Drugs
[0041] (1) Test substance
[0042] 20-(R)-Notoginsenoside Ft1 was fully ground in a mortar, and prepared with 0.5% sodium carboxymethylcellulose to make solutions with final concentrations of 120 mg / kg, 80 mg / kg, 40 mg / kg, and 20 mg / kg. Ready to use daily.
[0043] (2) Positive control drug
[0044] Cyclophosphamide for injection, approved by the Chinese National Medicines Agency H32020857, Jiangsu Shengdi Pharmaceutical Co., Ltd. Dilute to 2mg / mL with normal saline during the experiment.
[0045] 2. Animals
[0046] (1) Strain and source
[0047] SPF grade ICR mice, female, weighing 20-22 g, were provided by the Experimental Animal Center of Kunming Medical University, production license number: SCXK (Dian) K2015-0002, license issuing authority: Kunming Science and Technology Bureau. Adaptive feeding 5 days into the experiment.
[0048] (2) Feed...
Embodiment 3
[0065] 20-(R)-Notoginsenoside Ft1 (NotoginsenosideFt1) in vitro immune activity test:
[0066] 1. Test drug
[0067] 20-(R)-notoginsenoside Ft1, dissolved in DMSO to prepare 40mmol / L stock solution, stored at -20°C, and diluted with RPMI-1640 medium to final concentrations of 10umol / L, 5umol / L, 2.5umol in experiments / L, 1.25umol / L, 0.625umol / L, 0.3875umol / L.
[0068] 2. Main instruments
[0069] MS104S / PL600-S electronic analytical balance, METTLER TOLEDO, Switzerland; QT-1 vortex mixer, Shanghai Qite Instrument Analysis Instrument Co., Ltd.; carbon dioxide incubator, American Thermo-fisher Epoch continuous wavelength microplate reader, American Bio-Tek; Micropipettes, eppendorf.
[0070] 3. Main reagents
[0071] RPMI-1640 medium was purchased from BI Company (Cat. No. 0011616); fetal bovine serum was purchased from BI Company in the United States, Concanavalin A (ConcanavalinA, ConA, Cat. No.: C2272), bacterial lipopolysaccharide (LPS, Cat. No.: L2630), MTT All were pu...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


